The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.
This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,490 trial records at the last sync on 25 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.
This page shows the 10 of those trials with a site in Type 2 diabetes mellitus.
10 of the 2,500 most recently authorised trials in this register list a site in Type 2 diabetes mellitus; 5 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.
| Phase | Trials | Share |
|---|---|---|
| Phase III | 5 | 50% |
| Phase I | 2 | 20% |
| Phase I/II | 1 | 10% |
| Phase II | 1 | 10% |
| Phase IV | 1 | 10% |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca AB | 5 |
| Alnylam Pharmaceuticals Inc. | 1 |
| Corxel Pharmaceuticals Inc. | 1 |
| Jiangsu Hengrui Pharmaceuticals Co. Ltd. | 1 |
| Tecnimede-Sociedade Tecnico-Medicinal S.A. | 1 |
| Universita' Degli Studi Di Napoli Federico II | 1 |